Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
Hand-out
Press Releases
March 3, 2025

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User

bradford

The Bradford Era

Local & Social